<DOC>
	<DOCNO>NCT00988780</DOCNO>
	<brief_summary>The purpose study determine Maraviroc administration decrease IRIS incidence HIV infect patient initiate ARV therapy .</brief_summary>
	<brief_title>Maraviroc ( CCR5 ) Antagonism Decrease Incidence Immune Reconstitution Inflammatory Syndrome HIV-Infected Patients</brief_title>
	<detailed_description>This randomize , double blind , placebo-controlled , multicenter study test utility CCR5 antagonist ( Maraviroc ) adjuvant standard HAART regimen decrease incidence Immune Reconstitution Inflammatory Syndrome ( IRIS ) HIV-infected patient naïve antiretroviral treatment . The study duration 60 week , 276 subject ( 138 per arm ) recruit . The population include HIV-infected patient start antiretroviral ( ARV ) therapy participate center Mexico South Africa CD4 T cell count &lt; 100 cells/ul . Subjects randomize receive either Maraviroc ( study drug ) placebo addition background ARV therapy . The background antiretroviral regimen subject : Efavirenz 600mg QD + Tenofovir 300 mg / Emtricitabine 200 mg QD ; subject randomize one follow arm : Arm A : background ARV + maraviroc 600mg po BID ; Arm B : background ARV + placebo po BID . Patients follow 48 week . The primary endpoint occurrence define IRIS event week 24 follow . The success ARV therapy also evaluate virologic immunologic response 24 48 week . Three immunology sub-studies plan : 1 ) Sub-study A conform subgroup 40 subject ( 20 Mexico 20 South Africa ) , additional blood sampling perform evaluate expression immune activation marker ; movement central memory T cell cell cycle frequency expandable pathogen-reactive CD4+ CD8+ T cell circulation ; 2 ) Sub-study B conform another subgroup 60 subject ( South Africa ) , additional blood sampling perform evaluate monocyte CD4 T cell gene expression relate activation-induced apoptosis cytokine secretion . ; 3 ) Sub-study C evaluate incidence thromboembolic disease study patient along baseline evaluation possible bio-markers pro-coagulant state .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immune Reconstitution Inflammatory Syndrome</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV1 infection , document licensed rapid test kit confirm Western blot ELISA test kit time prior study enrollment . Plasma HIV1 RNA acceptable alternative confirmatory test . Men woman age &gt; 18 year . Have receive antiretroviral treatment enter study . Patients receive Single dose nevirapine duration AZT PMTC consider ARV naïve . CD4+ cell count &lt; /=100 cells/mm3 obtain within 90 day prior study entry . HIV RNA level &gt; 1,000 copies/mL obtain within 90 day prior study entry . Patients opportunistic HIVrelated infection may include accord clinical judgment main investigator center patient ready able start ARV therapy . Laboratory value obtain within 30 day prior study entry : Absolute neutrophil count ( ANC ) &gt; 500/mm3 . Hemoglobin &gt; 8.0 g/dL . Platelet count &gt; 50,000/mm3 . AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase minor 5 time ULN . Total bilirubin minor 2.5 time ULN . Creatinine clearance minor 50* mL/min estimate CockcroftGault equation Creatinine Clearance &gt; 50ml/min calculate formal creatinine clearance measurement All woman reproductive potential ( reach menopause undergone hysterectomy , oophorectomy , tubal ligation ) must negative serum urine bHCG pregnancy test perform within 7 day study entry . Female subject reproductive potential ( reach menopause undergone hysterectomy , oophorectomy , tubal ligation ) whose male partner undergone successful vasectomy resultant azoospermia azoospermia reason , eligible without require use contraception . Documentation menopause , sterilization ( hysterectomy , oophorectomy , tubal ligation , vasectomy ) azoospermia patientreported history acceptable . All subject must agree participate conception process ( i.e. , active attempt become pregnant impregnate , sperm donation , vitro fertilization ) , participate sexual activity could lead pregnancy , female study volunteer/male partner must agree use form contraception specify note receive protocolspecified medication ( ) one month stop medication ( ) . Ability willingness subject legal guardian/representative give write informed consent . Pregnancy breastfeed . Active neoplasia previous history neoplasia . ( Except localize non visceral Kaposi´s Sarcoma ; localize squamous basal cell carcinoma skin , intraepithelial cervical neoplasia grade III less ) . Use follow drug within 180 day prior study entry : systemic cancer chemotherapy , systemic investigational agent , immunomodulators ( growth factor , immune globulin , interleukin , interferon ) . Use systemic corticosteroid last 2 week prior randomization . Decompensated liver disease ( define stage C ChildPugh classification ) beginning study . An altered mental status opinion investigator , compromise adherence protocol . Allergy/sensitivity study drug ( ) formulation substitute another agent describe section 5.1 Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Serious illness render subject unable take antiretroviral study regimen . Serious medical illness opinion investigator compromise adherence and/or follow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Immune reconstitution inflammatory syndrome</keyword>
	<keyword>CCR5 antagonist</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>HIV</keyword>
	<keyword>treatment naive</keyword>
</DOC>